References:

- 1. Endrikat J, Barbati R, Scarpa M, Jost G, Ned A. Accuracy and Repeatability of Automated Injector Versus Manual Administration of an MRI Contrast Agent Results of a Laboratory Study. *Invest Radiol.* Jan 2018;53(1):1–5.
- 2. McDermott M, Kemper C, Barone W, Jost G, Endrikat J. Impact of CT Injector Technology and Contrast Media Viscosity on Vascular Enhancement: Evaluation in a Circulation Phantom. *Br J Radiol*. May 1 2020;93(1109):20190868.
- 3. Jost G, Endrikat J, Pietsch H. The Impact of Injector-Based Contrast Agent Administration on Bolus Shape and Magnetic Resonance Angiography Image Quality. *Magn Reson Insights*. 2017;10:1178623x17705894.
- 4. Bayer. Salient Operation Manual. 2019.
- 5. Cozzi A, Magni V, Zanardo M, Schiaffino S, Sardanelli F. Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance. Radiology. 2022;302(3):568–581. doi:10.1148/radiol.211412.
- 6. Bicchierai G, Tonelli P, Piacenti A, De Benedetto D, Boeri C, Vanzi E, Bianchi S, Cirone D, Kaur Gill M, Miele V, Nori J. Evaluation of contrast-enhanced digital mammography (CEDM) in the preoperative staging of breast cancer: Large-scale single-center experience. Breast J. 2020;26(7):1276–1283. doi:10.1111/tbj.13766.
- 7. Houben IPL, Van de Voorde P, Jeukens CRLPN, Wildberger JE, Kooreman LF, Smidt ML, Lobbes MBI. Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits. *Eur J Radiol*. 2017;94:31–37. doi:10.1016/j. ejrad.2017.07.004-6.
- 8. WHO. Current and future burden of breast cancer: global statistics for 2020 and 2040. Accessed April 2025. https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040/#:~:text=Breast%20cancer%20is%20 the%20most,between%20countries%20and%20world%20regions.
- 9. Chang L, Weiner LS, Hartman SJ, Horvath S, Jeste D, Mischel PS, Kado DM. Breast cancer treatment and its effects on aging. *J Geriatr Oncol.* 2019;10(2):346–355. doi:10.1016/j.jqo.2018.07.010.

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorized Bayer representative for the most current information.

The patient data that appear in this document are fictitious protected health information (PHI) and/or actual PHI from which all personally identifiable information (PII) has been removed or otherwise anonymized. No personally identifiable information is shown.

Bayer, the Bayer Cross, MEDRAD Salient, MEDRAD, and Salient are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2025 Bayer. This material may not be reproduced, displayed, modified or distributed without the express prior written consent of Bayer.

See the Possible. Create the Future.

> BAYER IN RADIOLOGY



Bayer A/S

Arne Jacobsens Allé 13 DK-2300 København S Danmark

more info on: www.radiology.bayer.dk



Manufacturer

Bayer Medical Care Inc. 1 Bayer Drive Indianola, PA 15051-0780 U.S.A.

Phone: +1-412-767-2400 +1-800-633-7231

Fax: +1-412-767-4120



Authorized European Representative

Bayer Medical Care B.V. Avenue Céramique 27 6221 KV Maastricht The Netherlands

Phone: +31 (0) 43-3585602 Fax: +31 (0) 43-3656598







Bringing Simplicity to Contrast Enhanced Mammography (CEM)





Clear Direction With MEDRAD® Salient

The MEDRAD® Salient Single System has been engineered to combine innovation and mobility in order to bring simplicity and reliability to your suite.





Simplicity

- > Intuitive, icon-driven interface
- Flexible workflow and software architecture
- > Single-action syringe loading
- Minimal installation with battery operation for total mobility



Reliability

- Dependable, reproducible flow rates and pressures that can consistently deliver injection protocols
- Provides a maximum pressure up to 300 psi and up to 10 mL/s
- Power injection enables accurate and repeatable contrast administration¹⁻⁴



"The main strengths and benefits are: speed, ease of programming and the wireless connection that allows it to move around the CT room."

Technologist, private practice, Colombia about Salient

Value Range Injector Needs Report (2020)






Your Partner for Contrast-Enhanced Mammography⁵⁻⁷

Salient can support a wide range of procedures, including contrast-enhanced mammography (CEM).

Several research studies demonstrate⁵⁻⁷ the efficacy and importance of CEM in breast cancer detection and management. CEM can facilitate early diagnosis of breast cancer, which is crucial to providing optimal treatment options. Breast cancer is the most commonly diagnosed cancer globally,⁸ but with early detection and intervention, it is also one of the most treatable.⁸





(Main Features and Benefits



Versatility in Your Suite

The straightforward design of Salient offers flexibility for your daily operations.

- Cordless configuration:
 Helps keep floor free of cords for a safer clinical environment
- Compact design:
 Enhances mobility
 Enables easy transport and storage
- Extensive Applications: Easily performs CEM injection protocols*
- Customized protocols:
 Allows customized protocols up to six phases
 Saves up to 20 customized injection protocols



Additional Tools for Enhanced Efficiency

In addition to Salient Single can be further tailored with the following accessories and features:

- > Wireless control room monitor
- > Available scanner interface: ISI2
- Protocol Assistant Tool (PAT)
- > Assurance: Salient has indications for x-ray diagnostic procedures, including CEM.



Control room monitor with the Protocol Assistant Tool (PAT)


^{*}Example protocol for CEM. 1.5 mls/kg at 2-4 mls/sec.





Bayer Is Your Partner


MEDRAD® injectors can support you in achieving diagnostic image quality for your patients and workflow efficiency in your CEM procedures.



Example protocol for fictional patient.

- Our Service and Application Specialists provide quality service and solutions to meet your clinical, financial, and operational needs.
- To learn more about MEDRAD® Salient Single and other Bayer products, please speak to your local representative.





MEDRAD® Salient Technical Specifications

Functional

Maximum pressure	300 psi	
Flow rate	0.1 to 10 mL/s	
Maximum volume	190 mL	
Multi-phase protocols	Up to six phases. Storage for 20 different named protocols	
Manual fill rate	Up to 10 mL/s	
Auto fill rate	Up to 10 mL/s	

Controls

Base	Line power, IEC inlet, on/off switch	
Head	5.7" LCD touch screen, arm button, on/off soft switch	
Infrared remote control	Inject start/stop	

Mechanical

Weight	22.9 kg (Single)
Height	1315 mm
Floor area	500 mm x 500 mm
No. of wheels	4 casters, all individually locking

Electrical

Line voltage	100 – 230 VAC
Line frequency	50/60 Hz
Battery operation	Dual batteries, sealed lead acid
Mains power operation	Simultaneous operation and battery charging
Contrast heat maintainer (one (1) included)	37°C +/- 4°C, 5W

Ordering Details

PART NAME	PART NO.
Salient Single Injector	DC009S
Salient Single Injector With Remote Control Unit	DC009SW
Scanner Interface Box (optional)	ISI2
Connector Tubing Single (box of 50)	ZY5151
Syringe With Quick Fill Tube (box of 50)	ZY6322
Syringe With Fill Spike (box of 50)	ZY6323
Syringe With Fill Spike, Single LPCT (box of 50)	ZY6324
Syringe With Quick Fill Tube, Single LPCT (box of 50)	ZY6325
Heat Maintainer (one (1) included)	DC022
Operation Manual – Multilanguage CD (one (1) included)	MN040015